Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 39Ovarian Neoplasms 32Triple Negative Breast Neoplasms 19Prostatic Neoplasms 17Fallopian Tube Neoplasms 16Neoplasm Metastasis 14Pancreatic Neoplasms 9Neoplasms 9Endometrial Neoplasms 9Carcinoma, Non-Small-Cell Lung 7Small Cell Lung Carcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Glioma 6Stomach Neoplasms 5Sarcoma 5Lung Neoplasms 5Glioblastoma 5Squamous Cell Carcinoma of Head and Neck 4Metastatic Castration-resistant Prostate Cancer 4Carcinoma, Ovarian Epithelial 4Solid Tumors 3Recurrence 3Osteosarcoma 3Neuroendocrine Tumors 3Lymphoma, Non-Hodgkin 3Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms, Castration-Resistant 2

Interventions

Injections 6pembrolizumab 5toripalimab 3tislelizumab 3senaparib 3Bevacizumab 3sintilimab 2Technetium 2Specimen Handling 2Nivolumab 2Ipilimumab 2Fluorodeoxyglucose F18 2Carboplatin 2Blood Specimen Collection 2zimberelimab 1tumor-cells apoptosis factor, human 1tazemetostat 1spartalizumab 1sacituzumab govitecan 1rucaparib 1osimertinib 1olaparib 1etoposide phosphate 1enzalutamide 1envafolimab 1cemiplimab 1cedazuridine 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Ultrasonography, Doppler 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor × olaparib × 1 year × Clear all
NCT05522491 2025-12-11

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Hebei Medical University Fourth Hospital

Phase 2 Not yet recruiting
30 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡